Secular trends of hospitalization with vancomycin-resistant Enterococcus infection in the United States, 2000-2006

Infection Control and Hospital Epidemiology

Volumn 30, Issue 2, 2009, Pages 184-186

  Ramsey, Andrew M ^a   Zilberberg, Marya D ^a,b  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b EviMed Research Group LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALIZATION; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; UNITED STATES; VANCOMYCIN; VANCOMYCIN RESISTANCE; YOUNG ADULT;

EID: 58849090457     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/593956     Document Type: Article

References (10)

1. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136:834-844.
2. Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB. Methicillin-resistant Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis 2005; 11:868-872.
3. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12:409-415.
4. Zilberberg MD, Shorr AF, Kollef MH. Secular trends in candidemia hospitalizations in the US, 2000-2005. Infect Control Hosp Epidemiol 2008; 29:978-980.
5. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14:929-931.
6. Rafferty ME, McCormick MI, Bopp LH, et al. Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay. Infect Control Hosp Epidemiol 1997; 18:342-344.
7. HCUPnet. Healthcare Cost and Utilization Project (HCUP). 2000-2004. Agency for Healthcare Research and Quality, Rockville, MD. Available at: http://www.ahrq.gov/HCUPnet/. Accessed May 24, 2008.
8. Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46:668-674.
9. Carmelli Y, Eliopoulis G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002; 162:2223-2228.
10. Ofner-Agostini M, Johnston BL, Simor AE, et al. Vancomycin-resistant enterococci in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2005. Infect Control Hosp Epidemiol 2008; 29:271-274.